MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202617015576 A) filed by Ratio Therapeutics, Inc., Boston, on Feb. 12, for 'fibroblast activation protein-targeted compositions and methods of use thereof.'
Inventor(s) include Amor-Coarasa, Alejandro; Babich, John, W.; Dimagno, Stephen; and Orcutt, Kelly.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "Disclosed is a compound represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof. The variables of structural formula (I) are described herein. The compound of the invention can be attached to chelating groups for radionuclide binding and are therefore suitable for radioimaging and/or radiotherapy applications, for example the disclosed compounds can be radiolabeled with a positron emitter such as 18F, 68Ga or 64Cu, and used for positron emission tomography (PET). Alternatively, the compounds can be radiolabeled with an alpha particle emitter such as 225 Ac, a beta particle emitter such as 67Cu or 177Lu, or an Auger electron emitter (e.g. 111In, 67Ga, 99mTc, 195mPt, 125I and 123I). The compounds can also be attached to a cytotoxic agent for targeted delivery of the cytotoxic agent to tumors, for example conjugated to gemcitabine or doxycycline, or a venom. Likewise, the compounds can be conjugated to compounds having physiological effects, such as TLR agonists to stimulate the immune response of a recipient."
The patent application was internationally filed on July 26, 2024, under International application No.PCT/US2024/039697.
Disclaimer: Curated by HT Syndication.
